======= ILF2 ======= == Gene Information == * **Official Symbol**: ILF2 * **Official Name**: interleukin enhancer binding factor 2 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=3608|3608]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q12905|Q12905]] * **Interactions**: [[https://thebiogrid.org/search.php?search=ILF2&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20ILF2|Open PubMed]] * **OMIM**: [[https://omim.org/entry/603181|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Appears to function predominantly as a heterodimeric complex with ILF3. This complex may regulate transcription of the IL2 gene during T-cell activation. It can also promote the formation of stable DNA-dependent protein kinase holoenzyme complexes on DNA. Essential for the efficient reshuttling of ILF3 (isoform 1 and isoform 2) into the nucleus. {ECO:0000269|PubMed:10574923, ECO:0000269|PubMed:11739746, ECO:0000269|PubMed:21123651, ECO:0000269|PubMed:9442054}. |DZF| |tertiary granule lumen| |transferase activity| |specific granule lumen| |double-stranded RNA binding| |ficolin-1-rich granule lumen| |ribonucleoprotein complex| |neutrophil degranulation| |neutrophil activation involved in immune response| |neutrophil mediated immunity| |neutrophil activation| |granulocyte activation| |leukocyte degranulation| |myeloid leukocyte mediated immunity| |myeloid cell activation involved in immune response| |myeloid leukocyte activation| |leukocyte activation involved in immune response| |cell activation involved in immune response| |transcription, DNA-templated| |nucleic acid-templated transcription| |RNA biosynthetic process| |regulated exocytosis| |leukocyte mediated immunity| |exocytosis| |nucleolus| |leukocyte activation| |secretion by cell| |export from cell| |cell activation| |immune effector process| |nucleobase-containing compound biosynthetic process| |secretion| |heterocycle biosynthetic process| |aromatic compound biosynthetic process| |organic cyclic compound biosynthetic process| |RNA binding| |DNA binding| |ATP binding| |positive regulation of transcription, DNA-templated| |cellular nitrogen compound biosynthetic process| |positive regulation of nucleic acid-templated transcription| |positive regulation of RNA biosynthetic process| |RNA metabolic process| |cellular macromolecule biosynthetic process| |positive regulation of RNA metabolic process| |macromolecule biosynthetic process| |immune response| |positive regulation of nucleobase-containing compound metabolic process| |positive regulation of macromolecule biosynthetic process| |extracellular region| |vesicle-mediated transport| |positive regulation of cellular biosynthetic process| |positive regulation of gene expression| |membrane| |gene expression| |positive regulation of biosynthetic process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp3|Actinomycin-D 0.001μM R00 exp3]]|-2.02| |[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|1.81| ^Gene^Correlation^ |[[:human genes:i:ints6|INTS6]]|0.448| |[[:human genes:c:cdc73|CDC73]]|0.446| |[[:human genes:r:rbm39|RBM39]]|0.428| |[[:human genes:c:ctr9|CTR9]]|0.42| |[[:human genes:b:brd2|BRD2]]|0.417| Global Fraction of Cell Lines Where Essential: 524/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|1/1| |bile duct|22/28| |blood|23/28| |bone|16/26| |breast|19/33| |central nervous system|42/56| |cervix|3/4| |colorectal|11/17| |esophagus|8/13| |fibroblast|1/1| |gastric|11/16| |kidney|16/21| |liver|12/20| |lung|47/75| |lymphocyte|11/16| |ovary|21/26| |pancreas|20/24| |peripheral nervous system|11/16| |plasma cell|9/15| |prostate|1/1| |skin|18/24| |soft tissue|6/9| |thyroid|2/2| |upper aerodigestive|15/22| |urinary tract|24/29| |uterus|3/5| == Essentiality in NALM6 == * **Essentiality Rank**: 417 * **Expression level (log2 read counts)**: 8.23 {{:chemogenomics:nalm6 dist.png?nolink |}}